How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

441. Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy (PubMed)

Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy Young adult mice were inoculated with herpes simplex virus type 2 (HSV-2) in the ear pinna. A relatively severe infection resulted, and 45% of the mice died by 11 days postinfection. Therapy at 1 mg/ml by means of the drinking water with either famciclovir for periods of 5 or 10 days or valaciclovir for 5, 10, 15, or 20 days decreased clinical signs and reduced mortality to 15 (...) % or less. Throughout a period of 27 days, mice were tested daily for the presence of infectious virus in the ear pinna, brain stem, and ipsilateral trigeminal ganglia. Virus was cleared from these tissues in surviving, untreated animals by 12 days postinfection, and no infectious virus was detected subsequently in any tissue. Furthermore, no infectious virus was detected after day 9 in mice that had been treated with famciclovir. In mice that had received valaciclovir therapy, however, infectious virus

Full Text available with Trip Pro

2000 Antimicrobial Agents and Chemotherapy

442. Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy (PubMed)

Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy Since the introduction of antiviral compounds such as lamivudine and famciclovir in the treatment schedules of patients with chronic hepatitis B virus (HBV) infection, the accumulation of a variety of mutations in the HBV polymerase gene has been observed. The selection of these mutations is generally considered the cause of viral nonresponsiveness and treatment failure. Therefore

Full Text available with Trip Pro

2000 Journal of clinical microbiology

443. Translating Statistics for Use in the Clinic (PubMed)

Translating Statistics for Use in the Clinic 9346459 1997 11 21 2018 12 01 0884-8734 12 10 1997 Oct Journal of general internal medicine J Gen Intern Med Translating statistics for use in the clinic. 626-8 Atkins C D CD eng Case Reports Journal Article United States J Gen Intern Med 8605834 0884-8734 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic use Breast Neoplasms epidemiology prevention (...) & control Clinical Trials as Topic methods Data Interpretation, Statistical Famciclovir Female Herpes Zoster diagnosis drug therapy Humans Male Mammography Middle Aged Models, Statistical Patient Education as Topic Sensitivity and Specificity 1997 11 5 1997 11 5 0 1 1997 11 5 0 0 ppublish 9346459 PMC1497176

Full Text available with Trip Pro

1997 Journal of General Internal Medicine

444. Management of herpes simplex and varicella-zoster virus infections. (PubMed)

agents, famciclovir and valacyclovir hydrochloride, have been approved for the short-term treatment of recurrent genital herpes simplex virus and recurrent zoster in nonimmunocompromised hosts. Famciclovir and valacyclovir demonstrate superior pharmacokinetics compared with acyclovir and allow for less frequent daily dosing with higher achievable serum drug concentrations. The attenuated live varicella virus vaccine is now available in the United States and prevents primary varicella-zoster virus

Full Text available with Trip Pro

1997 Western Journal of Medicine

445. Graded challenge in an aciclovir allergic patient (PubMed)

Graded challenge in an aciclovir allergic patient An immunocompetent woman presented with a hypersensitivity skin reaction following suppressive therapy with aciclovir for recurrent culture proved genital herpes simplex virus infection. She developed a similar reaction when treatment was changed to famciclovir. Without antiviral suppression her recurrences were frequent and distressing. Graded challenge was performed and she became tolerant to aciclovir. She successfully continued suppressive

Full Text available with Trip Pro

2001 Sexually transmitted infections

446. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice (PubMed)

Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice Acyclovir (ACV) resistant herpes simplex virus (HSV) isolates can be readily selected in animal infection models receiving suboptimal ACV treatment, however no comparative studies of the emergence of resistance following suboptimal treatment with valacyclovir (VCV) or famciclovir (FCV), the prodrugs of acyclovir and penciclovir, respectively, have been reported.Mice

Full Text available with Trip Pro

2001 BMC infectious diseases

447. Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

to screening Absence of Co-Infection with hepatitis C virus (HCV) or hepatitis D virus (HDV) Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease Less that 1/2 weeks of prior therapy with nucleoside/nucleotide analogue (excluding lamivudine) with activity against HBV (including e.g. famciclovir, tenofovir, ganciclovir, adefovir). No receipt of any of these therapies within 24 weeks prior to randomization into this study. Contacts and Locations Go to Information from

2002 Clinical Trials

448. A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.

, immunomodulatory or corticosteroid therapy Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection Previous treatment with interferon must have ended at least 6 months prior to screening visit History of ascites, variceal hemorrhage or hepatic encephalopathy Co-infection with HCV or HIV Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein) Contacts and Locations Go to Information from the National Library of Medicine

2002 Clinical Trials

449. A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

of age (or minimum age required in a given country) with history of chronic hepatitis B infection; HBeAg negative, anti-HBeAb positive; Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV); Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease; Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine

2002 Clinical Trials

450. A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

., adefovir, famciclovir and lamivudine) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035633 Sponsors and Collaborators Bristol-Myers Squibb More Information Go to Additional Information: Publications of Results: Layout table for additonal

2002 Clinical Trials

451. Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus

receiving immunosuppressive therapy, subjects with malignancy or subjects who acknowledge being seropositive for HIV. Subjects with a history of 10 or more HSV recurrences per year. Impaired real function as defined by serum creatine greater than 1.5 mg/dl (133uM). Impaired hepatic function as defined by an alanine transaminase (ALT) level greater than 3 times the normal upper limit. Known hypersensitivity to acyclovir, valaciclovir, famciclovir, or ganciclovir. Malabsorption syndrome or other gastro

2000 Clinical Trials

452. Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir

) for acute therapy of the current episode of herpes simplex encephalitis (HSE). Patients who are unable to swallow oral medications at the time of study drug randomization (Day 0). Patients who are > 3 days beyond completion of treatment course with intravenous (IV) ACV. Patients who are expected to receive long-term (> 30 days/year) therapy with antiviral medications active against HSV [e.g. ACV, valacyclovir (VACV), famciclovir]. Contacts and Locations Go to Information from the National Library

2002 Clinical Trials

453. Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

than or equal to 28 days of age at the time of initial presentation with skin, eyes, and mouth (SEM) disease. Birth weight greater than or equal to equal to 800 grams. Exclusion Criteria: Infants with either grade 3 or grade 4 intraventricular hemorrhage (IVH) prior to study enrollment. Breast feeding infants whose mothers are taking acyclovir, valacyclovir, or famciclovir for >120 hours (>5 days). If at any point following enrollment the mother takes these antiviral drugs for >120 hours (>5 days

2002 Clinical Trials

454. Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

of initial presentation with CNS disease. Birth weight greater than or equal to 800 grams. Exclusion Criteria: Infants with either a grade 3 or grade 4 intraventricular hemorrhage (IHV) prior to study enrollment. Breast feeding infants whose mothers are taking acyclovir, valacyclovir, or famciclovir for greater than 120 hours (greater than 5 days). If at any point following enrollment the mother takes these antiviral drugs for greater than 120 hours (greater than 5 days), she will be asked to refrain

2002 Clinical Trials

455. Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS

neoplasia class III (CIN III) on Pap smear (Pap smear required within 6 months of starting study drug). Concurrent Medication: Excluded: Acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, topical trifluride, cidofovir injection or other systemic or topical drugs with anti-herpes activity. Required: >= 10 day course acyclovir at 1-4 gm/day po or 15mg/kg/day IV (not required if there is confirmed in vitro resistance to acyclovir). Contacts and Locations Go to Information from the National

1999 Clinical Trials

456. A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed with caution: Acyclovir. Famciclovir. Valaciclovir. Imipenem-cilastatin. Myelosuppressive agents. Patients must have: HIV

1999 Clinical Trials

457. Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

high-dose acyclovir (more than 800 mg twice daily), valacyclovir (more than 500 mg twice daily), cidofovir (more than 0.5 mg/kg per week), or famciclovir (more than 500 mg/day) except for limited treatment courses at higher doses for varicella-zoster virus infections Concurrent low-dose (≤ 0.5 mg/kg per week) cidofovir allowed for limited treatment courses Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2001 Clinical Trials

458. Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth

; no visceral dissemination (normal liver function tests, normal chest x-ray, etc.); negative CSF PCR result Birth weight at least 800 grams --Prior/Concurrent Therapy-- No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or famciclovir for longer than 120 hours or 5 days; no prior prophylactic acyclovir for risk of herpes simplex virus infection --Patient Characteristics-- Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage

2000 Clinical Trials

459. Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

coagulopathy Birth weight at least 800 grams --Prior/Concurrent Therapy-- No concurrent nursing from a mother who is receiving acyclovir, valacyclovir, or famciclovir for longer than 120 hours or 5 days --Patient Characteristics-- Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No prior grade 3 or 4 intraventricular hemorrhage Other: No infants known to be born to HIV positive women Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2000 Clinical Trials

460. Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

: AST or ALT no greater than 5 times upper limit of normal Renal: Creatinine clearance at least 30 mL/min Other: Not pregnant or nursing; negative pregnancy test; fertile patients must use effective contraception; no history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, or famciclovir Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact

2000 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>